David Kavanagh , Gianluigi Ardissino , Vicky Brocklebank , Romy N. Bouwmeester , Arvind Bagga , Rob ter Heine , Sally Johnson , Christoph Licht , Alison L.T. Ma , Marina Noris , Manuel Praga , Eric Rondeau , Aditi Sinha , Richard J.H. Smith , Neil S. Sheerin , H. Trimarchi , Jack F.M. Wetzels , Marina Vivarelli , Nicole C.A.J. Van de Kar , Larry A. Greenbaum , Zoltán Prohászka
{"title":"国际肾脏病学会溶血性尿毒症综合征国际论坛的成果。","authors":"David Kavanagh , Gianluigi Ardissino , Vicky Brocklebank , Romy N. Bouwmeester , Arvind Bagga , Rob ter Heine , Sally Johnson , Christoph Licht , Alison L.T. Ma , Marina Noris , Manuel Praga , Eric Rondeau , Aditi Sinha , Richard J.H. Smith , Neil S. Sheerin , H. Trimarchi , Jack F.M. Wetzels , Marina Vivarelli , Nicole C.A.J. Van de Kar , Larry A. Greenbaum , Zoltán Prohászka","doi":"10.1016/j.kint.2024.09.012","DOIUrl":null,"url":null,"abstract":"<div><div>Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"106 6","pages":"Pages 1038-1050"},"PeriodicalIF":14.8000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum\",\"authors\":\"David Kavanagh , Gianluigi Ardissino , Vicky Brocklebank , Romy N. Bouwmeester , Arvind Bagga , Rob ter Heine , Sally Johnson , Christoph Licht , Alison L.T. Ma , Marina Noris , Manuel Praga , Eric Rondeau , Aditi Sinha , Richard J.H. Smith , Neil S. Sheerin , H. Trimarchi , Jack F.M. Wetzels , Marina Vivarelli , Nicole C.A.J. Van de Kar , Larry A. Greenbaum , Zoltán Prohászka\",\"doi\":\"10.1016/j.kint.2024.09.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.</div></div>\",\"PeriodicalId\":17801,\"journal\":{\"name\":\"Kidney international\",\"volume\":\"106 6\",\"pages\":\"Pages 1038-1050\"},\"PeriodicalIF\":14.8000,\"publicationDate\":\"2024-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney international\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0085253824007051\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney international","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0085253824007051","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum
Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.
期刊介绍：
Kidney International (KI), the official journal of the International Society of Nephrology, is led by Dr. Pierre Ronco (Paris, France) and stands as one of nephrology's most cited and esteemed publications worldwide.
KI provides exceptional benefits for both readers and authors, featuring highly cited original articles, focused reviews, cutting-edge imaging techniques, and lively discussions on controversial topics.
The journal is dedicated to kidney research, serving researchers, clinical investigators, and practicing nephrologists.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
